A detailed history of Pathstone Family Office, LLC transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Pathstone Family Office, LLC holds 2,205,377 shares of CGTX stock, worth $1.12 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,205,377
Previous 2,205,377 -0.0%
Holding current value
$1.12 Million
Previous $4.04 Million 21.31%
% of portfolio
0.02%
Previous 0.06%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$1.56 - $3.38 $7,800 - $16,900
-5,000 Reduced 0.23%
2,205,377 $4.04 Million
Q2 2022

Oct 23, 2023

BUY
$1.5 - $3.45 $7,500 - $17,250
5,000 Added 0.23%
2,210,377 $4.66 Million
Q2 2022

Aug 15, 2022

BUY
$1.5 - $3.45 $3.32 Million - $7.63 Million
2,210,377 New
2,210,377 $4.66 Million

Others Institutions Holding CGTX

About COGNITION THERAPEUTICS INC


  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $11.6M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.